BTIG Research Reaffirms “Buy” Rating for Gain Therapeutics (NASDAQ:GANX)

Gain Therapeutics (NASDAQ:GANX)‘s stock had its “buy” rating reaffirmed by equities research analysts at BTIG Research in a report issued on Tuesday,Benzinga reports. They currently have a $5.00 price objective on the stock. BTIG Research’s price target suggests a potential upside of 146.91% from the company’s previous close.

Several other equities research analysts have also recently weighed in on GANX. Roth Mkm restated a “buy” rating on shares of Gain Therapeutics in a research report on Tuesday, May 12th. Weiss Ratings lowered shares of Gain Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, June 9th. Wall Street Zen raised shares of Gain Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Sunday, June 21st. Finally, Oppenheimer reissued an “outperform” rating on shares of Gain Therapeutics in a report on Wednesday, May 27th. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $7.50.

Gain Therapeutics Price Performance

GANX traded up $0.04 during trading on Tuesday, hitting $2.02. The company’s stock had a trading volume of 3,454,219 shares, compared to its average volume of 841,737. The firm’s 50 day moving average price is $1.82 and its two-hundred day moving average price is $2.17. The company has a quick ratio of 4.69, a current ratio of 4.69 and a debt-to-equity ratio of 0.02. Gain Therapeutics has a 12 month low of $1.41 and a 12 month high of $4.34. The stock has a market capitalization of $86.37 million, a price-to-earnings ratio of -3.47 and a beta of 0.16.

Gain Therapeutics (NASDAQ:GANX) last announced its earnings results on Monday, May 11th. The company reported ($0.13) EPS for the quarter, hitting the consensus estimate of ($0.13). During the same period in the prior year, the firm posted ($0.16) EPS. Sell-side analysts forecast that Gain Therapeutics will post -0.54 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Gain Therapeutics

Institutional investors have recently modified their holdings of the business. Marshall Wace LLP lifted its holdings in Gain Therapeutics by 849.3% in the fourth quarter. Marshall Wace LLP now owns 1,662,293 shares of the company’s stock valued at $5,353,000 after buying an additional 1,487,186 shares during the period. Potomac Capital Management Inc. acquired a new stake in Gain Therapeutics during the 4th quarter worth $3,252,000. Geode Capital Management LLC raised its position in shares of Gain Therapeutics by 15.6% during the 4th quarter. Geode Capital Management LLC now owns 397,942 shares of the company’s stock valued at $1,282,000 after acquiring an additional 53,796 shares during the last quarter. Jane Street Group LLC raised its position in shares of Gain Therapeutics by 234.5% during the 4th quarter. Jane Street Group LLC now owns 242,328 shares of the company’s stock valued at $780,000 after acquiring an additional 169,878 shares during the last quarter. Finally, State Street Corp lifted its stake in shares of Gain Therapeutics by 72.9% in the 4th quarter. State Street Corp now owns 157,537 shares of the company’s stock valued at $507,000 after purchasing an additional 66,400 shares during the period. Institutional investors and hedge funds own 11.97% of the company’s stock.

About Gain Therapeutics

Gain Therapeutics, Inc (NASDAQ: GANX) is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative and rare diseases. The company leverages its proprietary allosteric modulation platform, AlphaTarget, to discover and optimize small molecule modulators that bind to non-active sites on target proteins. By correcting protein folding and function, Gain aims to provide disease-modifying treatments with improved selectivity and reduced off-target effects.

Gain’s lead clinical candidate, GT-022, is being developed for Gaucher disease, a rare lysosomal storage disorder characterized by deficient enzyme activity.